Purpose: Pathogenicity predictors are an integral part of genomic variant interpretation but, despite 16 their widespread usage, an independent validation of performance using a clinically-relevant dataset 17
exome and diagnostic panel sequencing. Using these datasets, we evaluate the performance of 23 three recently developed meta-predictors, REVEL, GAVIN and ClinPred, and compare their 24 performance against two commonly used in silico tools, SIFT and PolyPhen-2. 25 26
Results: Although the newer meta-predictors outperform the older tools, the performance of all 27 pathogenicity predictors is substantially lower in the clinically-representative dataset. Using our 28 clinically-relevant dataset, REVEL performed best with an area under the ROC of 0.81. Using a 29
concordance-based approach based on a consensus of multiple tools reduces the performance due 30 to both discordance between tools and false concordance where tools make common 31 misclassification. Analysis of tool feature usage may give an insight into the tool performance and 32 misclassification. 33 34
Conclusion: Our results support the adoption of meta-predictors over traditional in silico tools, but 35 do not support a consensus-based approach as recommended by current variant classification 36 guidelines. 37 38 39 40 41 42
Keywords: pathogenicity, genomic medicine, meta-predictor, variant interpretation, variant 43 classification 44 1. INTRODUCTION 45 As the scale of genomic sequencing continues to increase, the classification of rare genomic variants 46 is becoming the primary bottle-neck in the diagnosis of rare monogenic disorder. Guidelines 47 published by the American College of Medical Genetics (ACMG) in 2016 1 have helped bring includes a large number of variant filtering steps in order to reduce the burden of manual variant 100 assessment 26 . 101 102
Here we evaluate and compare the performance of two traditional in silico pathogenicity prediction 103 tools commonly used for clinical variant interpretation (SIFT 5 and PolyPhen-2 9 ), and three meta-104 predictors (REVEL 14 , GAVIN 15 overall minor allele frequency (MAF) between 1% and 5% were selected. These variants were 122 deemed too common to be disease-causing but are not necessarily filtered out by next-generation 123 sequencing pipelines depending on the MAF thresholds used. Chromosomal locations with more 124 than one variant (multiallelic sites) were excluded. Any variants found to be present in the 125 'pathogenic' and 'neutral' datasets were removed from the both. 126 127 2.2 Clinical Dataset (n=1766, see Figure S1B and Supplemental Table S1 ) more accurately reflects 128 variants that might require classification in a clinical diagnostics laboratory following identification in 129 an exome or genome sequencing pipeline. Variants were selected from three sources. Group 1 130
('DDD') consists of pathogenic (n=687) and benign (n=533) missense variants identified from 13,462 131 families in the Deciphering Developmental Disorders (DDD) study that have been through multiple 132 rounds of variant filtering and clinical evaluation 26, 29 . Variants were identified through exome 133 sequencing and were reported to the patients' referring clinicians for interpretation and 134 confirmation in accredited UK diagnostic laboratories. All benign variants from this list were assessed 135 as having no contribution towards the patient's phenotype, and were present in either as 136 heterozygotes in monoallelic genes or homozygotes in biallelic genes classified according to the 137 Developmental Disorder Genotype-2-Phenotype database (DDG2P) 30 (data accessed 17/10/2019). 138
Group 2 ('Diagnostic') consisted of pathogenic (n = 322) and benign (n=23) missense variants 139 identified through Sanger sequencing, next-generation sequencing panel analysis or single gene 140 testing in an accredited clinical diagnostic laboratory. Variants were manually classified according to 141 the ACMG guidelines on variant interpretation 1 on a 5-point scale (data accessed 23/04/2019). 142
Group 3 ('Amish') consisted of benign missense variants (n = 53) identified through a Community 143
Genomics research study of 220 Amish individuals. Variants were identified through singleton exome 144 sequencing and were classified as benign based on population frequencies and zygosity within this 145 study. Two subgroups were manually selected and annotated based on inheritance pattern and 146 disease penetrance; subgroup (i) consisted of variants in genes that cause a dominantly-inherited 147 disorder with complete penetrance in childhood, for which the individual was clinically unaffected; 148 this list was curated by a consultant in clinical genetics; subgroup (ii) consisted of variants in all other 149
OMIM morbid genes (including those with incompletely penetrant dominant disorders and recessive 150 and X-linked inheritance), with MAF>5% in the Amish cohort and MAF≤0.01% in gnomAD (data 151 accessed 18/10/2019). 152 153 154 155
Transcript selection and variant annotation 156
For the open dataset, the canonical transcript was selected for each variant using the Variant Effect 157
Predictor (VEP) 31 . For the clinical dataset, the HGMD Professional RefSeq transcript was used, unless 158 absent from the database, in which case the MANE primary transcript was selected. Variants were 159 annotated with variant cDNA and protein nomenclature in reference to the selected transcript. 160
PolyPhen-2 and SIFT scores were annotated using VEP. REVEL and ClinPred scores were annotated 161 using flat files containing precomputed scores for all possible single nucleotide substitutions, and in 162 both cases, the combination of nucleotide position, nucleotide change and amino acid change was 163 sufficiently unique to identify a single record, i.e. transcript selection did not affect the scores. 164 GAVIN scores were generated through a batch submission to the GAVIN server. 165 166
2.4 Tool benchmarking 167
The performance of each of the tools was determined for both datasets. For SIFT, PolyPhen-2, REVEL 168
and ClinPred, the output of the analysis was a numerical score between 0 and 1. Initially, all tools 169
were analysed according to the criteria defined in their original publications, with the thresholds for 170 pathogenicity being ≤0.05 for SIFT, ≥0.9 for PolyPhen-2 and ≥0.5 for ClinPred. For REVEL, where no 171 threshold is recommended, a threshold of ≥0.5 was used. The categorical classification of GAVIN was 172 used directly ("Benign", "Pathogenic"; variants of uncertain significance ("VOUS") were removed). A 173 supplementary analysis was done for those tools with a numerical output (SIFT, PolyPhen-2, REVEL 174
and ClinPred), to more accurately compare their performance. A unique threshold was selected for 175 each tool to calculate the specificity when sensitivity was set to 0.9. In order to include GAVIN in this 176 analysis, a third analysis was performed, whereby each tool's specificity was measured when the 177 threshold was adjusted to set the sensitivity identical to that of GAVIN. 178 179 We compared the feature list of all tools benchmarked in this study (PolyPhen-2, SIFT, REVEL, GAVIN  188 and ClinPred) and, in the case of the meta-predictors, the tools that they use as part of their 189 algorithm (MPC 32 , MutPred 33 , VEST 34 , CADD 35 , DANN 36 , SNPEff 37 , FATHMM 38 , FitCons 39 and 190
MutationTaster 40 ). Features were split into five broad categories: Conservation, Genetic variation, 191
Functional evidence (nucleotide), Functional evidence (protein) and Amino acid properties (see 192 Figure 1 and Supplemental Figure S2) REVEL has the highest AUC for the clinical dataset (0.808). The two meta-predictors outperformed 217
SIFT and PolyPhen-2 in both datasets. In agreement with tool author benchmarking 14-16 the meta-218 predictors REVEL, ClinPred and GAVIN were highly proficient at classifying the variants in the open 219 dataset, achieving sensitivities of 0.87, 0.90 and 0.95, and specificities of 0.95, 1.00 and 0.98, 220 respectively. For variants in the clinical dataset, although the sensitivity each tool remained largely 221 constant, the specificity of all tools dropped considerably. For REVEL, ClinPred and GAVIN, specificity 222 is reduced to 0.62, 0.28 and 0.25, respectively [ Table 1] It was apparent that the threshold suggested by the tools' authors was not well-suited to both 241 datasets, given the tools' very high sensitivity but low specificity in the clinical dataset. In order to 242 correct for this we performed a supplementary analysis for those predictors which gave a numerical 243 output (SIFT, PolyPhen-2, REVEL and ClinPred). Here, a variable threshold was allowed for each tool 244
to give a common sensitivity of 0.9 (i.e. pathogenic variation is called correctly 90% of the time). The 245 threshold required to give a sensitivity of 0.9 in each tools is shown in Table S2 . The specificity of 246 each tool at the determined threshold is shown in Figure S3 . When allowed a variable threshold the 247 tools' specificity increased significantly, with PolyPhen-2, SIFT, REVEL and ClinPred achieving a 248 specificity of 0.67, 0.63, 0.93 and 0.99 for the open dataset, and 0.34, 0.33, 0.52 and 0.52 for the 249 clinical dataset, respectively. In order to include GAVIN in this analysis, a third analysis was 250 performed in which each tool was given a threshold to match the sensitivity achieved by GAVIN in 251 each of the datasets. The specificity of all five tools is shown in Figure S4 , and the sensitivity and 252 threshold for each tool is shown in Table S3 . 3
.3 Use of individual tools versus a consensus-based approach between multiple tools 262
In accordance with current variant classification guidelines, we investigated the effect of performing 263 a consensus-based analysis, using two commonly-used tools, SIFT and PolyPhen-2, and two meta-264 predictors, REVEL and ClinPred, to determine whether this combined approach has improved 265 sensitivity/specificity over the individual tools. Figure 4 shows the true concordance rate (variants 266 classified correctly by both tools), false concordance rate (variants classified incorrectly by both 267 tools) and discordance rate (variants for which the tools disagreed) for each of these tool pairings for 268 the pathogenic and benign variants in both datasets. Within the clinically-relevant dataset, the tools 269 are either falsely concordant or discordant for ~15% of pathogenic variants but ~77% of benign 270 variants. The sensitivity and specificity of this approach is shown in Figure 3 ] and with a higher specificity than GAVIN 291 in a direct (albeit suboptimal) comparison [ Figure S4 ]. While the REVEL team does not suggest a 292 strict threshold for categorisation, in our analysis for the clinical dataset, a threshold of 0.43 gave a 293 sensitivity of 0.9, and a specificity of 0.52, which is comparable to previous studies' threshold of 294 0.5 16 . 295 296
Current guidelines on the classification of variants indicate that evidence should only apply when 297 multiple tools are concordant 1 . However, the use of concordance introduces a third category to 298 variants classification (discordance), where there is disagreement between tools and therefore the 299 tools cannot be used as evidence to categorise the variant as either benign or pathogenic. Our data 300
show that the use of concordance between multiple tools gives a lower sensitivity and specificity 301 than the use of either of these tools in isolation, and furthermore that their performance is much 302 below that of the meta-predictors. 303 304
As with all similar studies, we were limited by the availability of novel variants not present in online 305
databases such as gnomAD. The use of under-represented and genetically isolated populations, such 306 as the Amish, allowed for the identification of a number of novel benign variants and suggests that 307 such populations may be a rich source for future studies. We also identified a number of both 308 pathogenic and benign variants in a clinical population through a translational research study (DDD). 309
While steps were taken to ensure that the benign variants attained from this group were indeed 310 benign (all variant were present within either monoallelic genes, or in biallelic genes in a 311 homozygous state, and were annotated by the referring clinician as having no contribution towards 312 the patient's clinical phenotype), nonetheless it cannot be guaranteed that the variants had no 313 impact of protein function. The study highlights the need for improved data-sharing between clinical 314 laboratories. While a number of online repositories exist for the sharing of rare pathogenic variants, 315 no such resource is available for the sharing of rare benign variants. 316 317
The study supports the adoption of in silico meta-predictors for use in variant classification according 318 to the ACMG guidelines, but recommends the use of a single meta-predictor over the application of 319 a consensus-based approach. Each of the tools utilises different though heavily overlapping data 320 sources and the feature list utilised by a tool should be carefully considered before the tool is 321
utilised. Our results also suggests that tools that utilise gnomAD data directly may have low 322 specificity when classifying rare or novel variants and that care should be taken when utilising these 323 tools in conjunction with the ACMG guidelines. Although use of a meta-predictor tools offers notable 324
advantages to the use of the previously available and widely adopted in silico tools, the remaining 325 issues to be addressed before they can be used as more at a level greater than supporting evidence 326 for clinical variant interpretation. 327
